|
1
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hilal L, Shahit M, Mukherji D,
Charafeddine M, Farhat Z, Temaraz S, Khauli R and Shamseddine A:
Prostate cancer in the Arab world: A view from the inside. Clin
Genitourin Cancer. 13:505–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Popiolek M, Rider JR, Andrén O, Andersson
SO, Holmberg L, Adami HO and Johansson JE: Natural history of
early, localized prostate cancer: A final report from three decades
of follow-up. Eur Urol. 63:428–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoffman RM, Gilliland FD, Adams-Cameron M,
Hunt WC and Key CR: Prostate-specific antigen testing accuracy in
community practice. BMC Fam Pract. 3:192002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nadler RB, Humphrey PA, Smith DS, Catalona
WJ and Ratliff TL: Effect of inflammation and benign prostatic
hyperplasia on elevated serum prostate specific antigen levels. J
Urol. 154:407–413. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adhyam M and Gupta AK: A review on the
clinical utility of PSA in cancer prostate. Indian J Surg Oncol.
3:120–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boddy JL, Pike DJ and Malone PR: A
seven-year follow up of men following a benign prostate biopsy. Eur
Urol. 44:17–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hugosson J, Carlsson S, Aus G, Bergdahl S,
Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E and Liljia H:
Mortality results from the Göteborg randomised population-based
prostate-cancer screening trial. Lancet Oncol. 11:725–732. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, et al: Screening and prostate-cancer mortality in a
randomized european study. N Engl J Med. 360:1320–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andriole GL, Crawford ED, Grubb RL III,
Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kuale PA, Reding
DJ, et al: Mortality results from a randomized prostate-cancer
screening trial. N Engl J Med. 360:1310–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stamey TA, McNeal JE, Yemoto CM, Sigal BM
and Johnstone IM: Biological determinants of cancer progression in
men with prostate cancer. JAMA. 281:1395–1400. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oesterling JE: Prostate specific antigen:
A critical assessment of the most useful tumor marker for
adenocarcinoma of the prostate. J Urol. 145:907–923. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thompson IM, Pauler DK, Goodman PJ, Tangen
CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford
ED, et al: Prevalence of prostate cancer among men with a
prostate-specific antigen level <or =4.0 ng per milliliter. N
Engl J Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Velonas VM, Woo HH, Remedios CG and
Assinder SJ: Current status of biomarkers for prostate cancer. Int
J Mol Sci. 14:11034–11060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kgatle MM, Kalla AA, Islam MM, Sathekge M
and Moorad R: Prostate cancer: Epigenetic alterations, risk
factors, and therapy. Prostate Cancer. 2016:56538622016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui
W, Hao M and Qiu L: MicroRNA-15a/16-1 cluster located at chromosome
13q14 is down-regulated but displays different expression pattern
and prognostic significance in multiple myeloma. Oncotarget.
6:38270–38282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yunxia Z and Hongying D: Low expression of
miR-192 in NSCLC and its tumor suppressor functions in metastasis
via targeting ZEB2. Open Life Sci. 11:293–297. 2016.
|
|
22
|
Botla SK, Savant S, Jandaghi P, Bauer AS,
Mücke O, Moskalev EA, Neoptolemos JP, Costello E, Greenhalf W,
Scarpa A, et al: Early epigenetic downregulation of microRNA-192
expression promotes pancreatic cancer progression. Cancer Res.
76:4149–4159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang R, Ma Y, Yu D, Zhao J and Ma P:
miR-377 functions as a tumor suppressor in human clear cell renal
cell carcinoma by targeting ETS1. Biomed Pharmacother. 70:64–71.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Shao J, Zhang X, Xu M and Zhao J:
microRNA-377 suppresses the proliferation of human osteosarcoma
MG-63 cells by targeting CDK6. Tumour Biol. 36:3911–3917. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song L, Xie X, Yu S, Peng F and Peng L:
MicroRNA-126 inhibits proliferation and metastasis by targeting
pik3r2 in prostate cancer. Mol Med Rep. 13:1204–1210. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun J, Fan Z, Lu S, Yang J, Hao T and Huo
Q: miR-192 suppresses the tumorigenicity of prostate cancer cells
by targeting and inhibiting nin one binding protein. Int J Mol Med.
37:485–492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferracin M, Veronese A and Negrini M:
Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev
Mol Diagn. 10:297–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Al-Kafaji G, Al Naieb ZT and Bakhiet M:
Increased oncogenic microRNA-18a expression in the peripheral blood
of patients with prostate cancer: A potential novel non-invasive
biomarker. Oncol Lett. 11:1201–1206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Kafaji G, Al-Mahroos G, Abdulla
Al-Muhtaresh H, Sabry MA, Abdul Razzak R and Salem AH: Circulating
endothelium-enriched microRNA-126 as a potential biomarker for
coronary artery disease in type 2 diabetes mellitus patients.
Biomarkers. 22:268–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keller A, Leidinger P, Bauer A, Elsharawy
A, Hass J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al:
Toward the blood-borne miRNome of human diseases. Nat Methods.
8:841–843. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitchell PS, Parkin RK, Kroh EM, Frit BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weber JA, Baxter DH, Zhang S, Huang KH,
Lee MJ, Galas DJ and Wang K: The microRNA spectrum in 12 body
fluids. Clin Chem. 56:1733–1741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Turchinovich A, Samato TR, Tonevitsky AG
and Burwinkel B: Circulating miRNAs: Cell-cell communication
function? Front Genet. 4:1192013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sita-Lumsden A, Dart DA, Waxman J and
Bevan CL: Circulating microRNAs as potential new biomarkers for
prostate cancer. Br J Cancer. 108:1925–1930. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Watahiki A, Macfarlane RJ, Gleave ME, Crea
F, Wang Y, Helgason CD and Chi KN: Plasma miRNAs as biomarkers to
identify patients with castration-resistant metastatic prostate
cancer. Int J Mol Sci. 14:7757–7770. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
D'Amico AV, Whittington R, Malkowicz SB,
Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA,
Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical
prostatectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA.
280:969–974. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Al-Kafaji G, Al-Mahroos G, Alsayed NA,
Hasan ZA, Nawaz S and Bakhiet M: Peripheral blood microRNA-15a as a
potential biomarker for type 2 diabetes mellitus and pre-diabetes.
Mol Med Rep. 12:7485–7490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Coppola V, de Maria R and Bonci D:
MicroRNAs and prostate cancer. Endocr Relat Cancer. 17:F1–F17.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
33:135–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang S, Aurora AB, Johnson BA, Qi X,
McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miko E, Margitai Z, Czimmerer Z, Varkonyi
I, Dezso B, Lányi A, Bacsó Z and Scholtz B: miR-126 inhibits
proliferation of small cell lung cancer cells by targeting SLC7A5.
FEBS Lett. 585:1191–1196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Du YY, Lin YF, Chen YT, Yang L,
Wang HJ and Ma D: The cell growth suppressor, mir-126, targets
IRS-1. Biochem Biophys Res Commun. 377:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang X, Wu H and Ling T: Suppressive
effect of microRNA-126 on oral squamous cell carcinoma in vitro.
Mol Med Rep. 10:125–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li XM, Wang AM, Zhang J and Yi H:
Down-regulation of miR-126 expression in colorectal cancer and its
clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sasahira T, Kurihara M, Bhawal UK, Ueda N,
Shimomoto T, Yamamoto K, Kirita T and Kuniyasu H: Downregulation of
miR-126 induces angiogenesis and lymphangiogenesis by activation of
VEGF-A in oral cancer. Br J Cancer. 107:700–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Meister J and Schmidt MH: miR-126 and
miR-126*New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
